Judge William C. Bryson has ordered Allergan to file a brief for a federal patent infringement case by Friday, October 13, after questioning whether the drug maker’s recent transfer of drug patents to a sovereign tribe was a “sham.”
Judge William C. Bryson has ordered Allergan to file a brief for a federal patent infringement case by Friday, October 13, after questioning whether the drug maker’s recent transfer of drug patents to a sovereign tribe was a “sham.” Allergan recently transferred patents for its dry-eye drug, Restasis, to the Saint Regis Mohawk Tribe, who invoked sovereign immunity against inter partes review (IPR) of the drug’s patents in exchange for a bulk payment of $13.75 million and an additional $15 million per year in royalties.
Bryson, who is presiding over an unrelated Hatch-Waxman litigation over Restasis, noted that the Irish drug maker had told the court that the Tribe would join Allergan as a co-plaintiff in the case, which it has not yet done despite being the new patent holder. Allergan is suing rival drug makers who have hoped to develop and market generics for Restasis. Bryson has ordered Allergan and the defendants in the case to file briefs “addressing the question of whether the Tribe should be joined as a co-plaintiff in this action, or whether the assignment of the patents to the Tribe should be disregarded as a sham.”
Allergan’s CEO, Brent Saunders, previously argued that the patent transfer would only have bearing on IPRs of its Restasis patents, and that its agreement with the Tribe would have “no impact” on the Federal District Court Hatch-Waxman litigation. However, Bryson’s order suggests that that the court may disagree with Saunders’ position. Dan Ravicher, JD, a professor of law at the University of Miami, told CNBC that "Once [representatives of the Tribe] appear in federal court, they've now waived their tribal immunity."
While Bryson’s forthcoming ruling in the case has the potential to impact Allergan’s ability to shield its patents through such arrangements, law makers are hoping to make further patent transfers to sovereign tribes illegal. Last Thursday, Senator Claire McCaskill (D-Missouri) announced that she has drafted legislation that would expressly prohibit the use of tribal sovereign immunity to block review of patents before the US Patent and Trademark Office. “Congress never imagined tribes would allow themselves to be used by pharmaceutical companies to avoid challenges to patents,” said McCaskill in a statement, “and this bill will shut the practice down before others follow suit.”
However, bigger legal challenges for the IPR process are underway, and the outcomes of those challenges could have a significant effect on the biosimilars marketplace. An argument before the Supreme Court in Oil States Energy Services v Greene’s Energy Group, a case that challenges the constitutionality of the IPR process, has been set for November 27; should IPRs be ruled unconstitutional, generic drug and biosimilar developers could lose an important tool by which to clear patents. Robert Cerwinski, JD, told The Center for Biosimilars® in a recent interview that, “Everybody in the biosimilars world is watching this Supreme Court matter pretty closely. The upshot is, if in fact the law that created IPRs is governed to be unconstitutional, Congress is going to have to take another shot at either modifying or redoing the statute that created IPRs. So, the potential impact on biosimilar applicants from having the IPR scheme eliminated entirely will be quite significant.”
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.